Dermata Q3: First Tome Revenue of $74K, $4.8M Cash, Going Concern Reaffirmed
DRMA sits 16% above its 52-week low of $0.603.
Summary
Dermata posted its first product revenue ($74K) in Q3 2026 but burned $7.6M over nine months, leaving $4.8M of cash that funds operations only into Q1 2027 with going concern doubt reaffirmed. A December 2026 court hearing with Villani and 10.0M outstanding warrants hang over the equity.
Key Events · Earnings and Guidance · DRMA
-
First Product Revenue: $74K
Net sales of $74,137 and cost of sales of $34,008 produced $40,129 gross profit (~54% margin) from the Tome Foundational Treatment, which began selling August 25, 2026.
-
Cash Runway to Q1 2027
Cash and equivalents were $4.82M at September 30, 2026, down from $7.52M at December 31, 2025; nine-month operating cash burn was $7.55M and management expects funding only into the first quarter of 2027.
-
Going Concern Doubt Reaffirmed
The filing states substantial doubt about the ability to continue as a going concern for one year, not alleviated by management's plans, with an accumulated deficit of $80.9M and a $7.64M nine-month net loss.
-
Villani Hearing Set for December
Villani's preliminary injunction was denied August 5, 2026 and the TRO vacated, but an evidentiary hearing on injunctive relief is scheduled for December 9, 10 and 14, 2026, and Villani seeks money damages in a parallel arbitration the company cannot yet estimate.
Analysis · DRMA · Life Sciences
Dermata's pivot from prescription drugs to direct-to-consumer skincare has finally produced real revenue: $74,137 in net sales and $40,129 of gross profit from the Tome Foundational Treatment launched August 25, 2026. Against a $7.6M nine-month net loss, however, those numbers are a rounding error. Cash fell to $4.8M from $7.5M at year-end, and management now says that funds operations only into the first quarter of 2027, with substantial doubt about going concern explicitly not alleviated by its plans. The ATM is fully used up, so the next capital raise will be a fresh dilutive event. Layered on top: the Villani litigation remains unresolved. The preliminary injunction was denied in August, but an evidentiary hearing is set for December 9, 10 and 14, 2026, and Villani is simultaneously pursuing money damages in arbitration. With 10.05M warrants outstanding against 4.93M shares, any recovery in the stock price would likely be met with warrant exercises and new issuance.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRMA was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.60 to $4.66. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.